The Global Monoclonal Antibody Therapeutics Market is valued at approximately USD 205.09 billion in 2023 and is anticipated to grow with a healthy growth rate of more than 15.0% over the forecast ...

The FDA approves INCY's Monjuvi in combination with rituximab and lenalidomide for relapsed/refractory follicular lymphoma, its second approved indication.

Following a complete response letter issued last October over CMC issues, CSL Behring LLC gained U.S. FDA approval June 16 of its humanized anti-factor XIIa monoclonal antibody, garadacimab (CSL-312), ...

Creative Biolabs recently rolled out a three-dimensional upgrade designed to make antibodies safer, more potent, and easier to develop. SHIRLEY, NY, UNITED STATES, June 18, 2025 /EINPresswire.com/ -- ...

Thus, TACI is a promising target for SLE treatment. Methods In this study, we discovered a novel anti-TACI antibody, GenSci-X002, by hybridoma and humanization approach to investigate its funtion on ...